<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133367</url>
  </required_header>
  <id_info>
    <org_study_id>05-154</org_study_id>
    <nct_id>NCT00133367</nct_id>
  </id_info>
  <brief_title>Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus</brief_title>
  <official_title>Phase II Study of Sequential Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus as Graft Versus Host Disease Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effectiveness of 2 drugs, tacrolimus and
      sirolimus, in preventing graft versus host disease (GVHD) after treatment with chemotherapy
      followed by donor cord blood transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The chemotherapy portion of the study involves the intravenous administration of
           fludarabine, for six days (Days 8, 7, 6, 5,4, and 3) before transplant, melphalan, for
           one day (Day 2) before transplant. Antithymocyte globulin, or thymoglobulin, will be
           given IV daily for 4 days (days 7, 5, 3, and 1 before transplant). This drug also helps
           to suppress the immune system, allowing the cord blood cells to grow and reproduce.

        -  Immunosuppression therapy consists of the drugs tacrolimus and sirolimus. The patient
           will receive these 3 days before the transplant and every day for 3-6 months after
           transplant. After the first 100 days post transplant, the doses of tacrolimus and
           sirolimus will begin to be reduced with the goal of having the patient off both drugs by
           6-9 months after transplant.

        -  After completion of conditioning therapy described above, the patient will receive 2
           cord blood units 1-6 hours apart. To help with engraftment, the patient will also
           receive G-CSF starting on day five after transplant, until the patients white blood
           cells recover.

        -  Follow-up visits will continue every 6 months after the last treatment dose and will
           last up to 2 years.

        -  Blood tests will be drawn frequently to test whether the donor's immune cells have
           engrafted as well as to test the levels of Tacrolimus and Sirolimus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effectiveness of tacrolimus and sirolimus in preventing graft versus host disease</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the days to neutrophil engraftment and platelet engraftment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the relapse rate and overall disease free survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Myelogenous Leukemia</condition>
  <condition>Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Given starting on day 5 after transplant until the subjects white blood cell count recovers.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithymocyte globulin</intervention_name>
    <description>Given intravenously for 4 days before transplant (days 7, 5, 3, 1).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Given intravenously for 4 days before transplant (days 7, 5, 3, 1).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given intravenously on day 2 before transplant.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematologic malignancies for whom allogeneic stem cell transplantation
             is deemed clinically appropriate

          -  Non-Hodgkin's lymphoma, or Hodgkin's lymphoma: in Complete Remission &gt;2 (second
             complete remission, third complete remission, etc) or in partial remission

          -  Multiple myeloma: relapsed

          -  Chronic lymphocytic leukemia, Rai stage III or IV, or lymphocyte doubling time of 6
             months, or stage I-II, having progressed after &gt; 2 chemotherapy regimens, in partial
             remission.

          -  Acute myelogenous or lymphoblastic leukemia in second or subsequent remission or in
             first remission with adverse cytogenetic or antecedent hematologic disorder

          -  Chronic myelogenous leukemia in accelerated or second stable phase, or imatinib
             resistant and not eligible for an ablative transplant

          -  Myelodysplasia, previously treated or not eligible for ablative transplant

          -  Age 18-65 years.

          -  ECOG performance status of 0, 1, or 2.

          -  Lack of 6/6 or 5/6 HLA-matched related, 10/10 matched unrelated donor, or unrelated
             donor not available within the time frame necessary to perform a potentially curative
             stem cell transplant.

        Exclusion Criteria:

          -  Cardiac disease:

               -  symptomatic congestive heart failure or

               -  radionuclide ventriculogram (RVG) or echocardiogram determined left ventricular
                  ejection fraction of &lt; 40%,

               -  active angina pectoris, or

               -  uncontrolled hypertension.

          -  Pulmonary disease:

               -  severe chronic obstructive lung disease, or

               -  symptomatic restrictive lung disease, or

               -  corrected DLCO of &lt; 50% of predicted.

          -  Renal disease:

               -  serum creatinine &gt; 2.0 mg/dl.

          -  Hepatic disease:

               -  serum bilirubin &gt; 2.0 mg/dl (except in the case of Gilbert's syndrome or
                  hemolytic anemia in which the bilirubin can be elevated greater than 2.0mg/dl),

               -  SGOT or SGPT &gt; 3 x normal.

          -  Neurologic disease:

               -  symptomatic leukoencephalopathy,

               -  active central nervous system (CNS) malignancy or other neuropsychiatric
                  abnormalities believed to preclude transplantation (previous CNS malignancy,
                  presently in complete remission [CR] is not exclusion).

          -  HIV antibody.

          -  Uncontrolled infection.

          -  Pregnancy or breast feeding mother.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K Ballen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Karen Ballen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hematologic malignancy</keyword>
  <keyword>Cord blood transfusion</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

